Prime Editing for Neurodegenerative Diseases

Prime Editing for Neurodegenerative Diseases

Prime editing is a next-generation CRISPR gene editing technology that offers unprecedented precision for making precise genetic modifications without requiring double-strand DNA breaks. This mechanism page explores how prime editing is being developed as a therapeutic approach for neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).

Overview

Prime Editing for Neurodegenerative Diseases

Prime editing is a next-generation CRISPR gene editing technology that offers unprecedented precision for making precise genetic modifications without requiring double-strand DNA breaks. This mechanism page explores how prime editing is being developed as a therapeutic approach for neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS).

Overview

Prime editing was first described by Liu et al. in 2019[@anzalone2019] and represents a major advancement over traditional CRISPR-Cas9 systems. Unlike conventional CRISPR approaches that rely on double-strand breaks and cellular repair pathways, prime editing directly writes new genetic information into the genome with high precision and minimal byproducts.

The technology has shown promise for treating hereditary neurodegenerative diseases by enabling:

• Precise correction of pathogenic point mutations
• Insertion of protective genetic variants
• Targeted epigenetic modifications
• All 12 types of point mutations (transitions and transversions)

Molecular Mechanism

Core Components

Prime editing utilizes a fusion protein consisting of:

Editing Process

The prime editing mechanism proceeds through several steps:

pegRNA Design

The pegRNA contains three critical regions:

• Spacer sequence (20 nt) — Directs the complex to the target site
• Primer binding site (PBS) (10-15 nt) — Initiates reverse transcription
• RTT template (10-20 nt) — Carries the desired edit

Advantages Over Traditional CRISPR

| Feature | Traditional CRISPR-Cas9 | Prime Editing |
|---------|----------------------|---------------|
| Double-strand breaks | Required | None |
| Off-target effects | Higher | Significantly reduced |
| Precision | Lower | Very high |
| Edit types | Limited to insertions/deletions | All 12 point mutations |
| Byproducts | Indels common | Minimal indels |
| Cellular repair | HDR (low efficiency) | Direct writing |

Key advantages include:

• No double-strand breaks: Eliminates risk of large chromosomal rearrangements
• Precision editing: Can install any of the 12 possible point mutations with high fidelity
• Reduced off-target activity: Studies show 10-100x fewer off-target edits compared to conventional Cas9
• Versatility: Can perform insertions, deletions, and all types of base substitutions

Applications in Alzheimer's Disease

APP Gene Correction

Mutations in the [APP](/genes/app) (Amyloid Precursor Protein) gene can lead to increased [amyloid-beta](/proteins/amyloid-beta) production, a hallmark of AD. Prime editing offers the ability to:

• Correct pathogenic [APP](/entities/app-protein) mutations (e.g., Swedish mutation, London mutation)
• Reduce amyloidogenic processing by modifying cleavage sites
• Introduce protective variants

APOE Allele Modification

The [APOE](/genes/apoe) gene has three common alleles (ε2, ε3, ε4) with varying AD risk:

• ε4 — Major genetic risk factor for late-onset AD
• ε2 — Protective against AD

Therapeutic Targeting

Prime editing enables:

• Direct correction of pathogenic mutations in early-onset AD
• Engineering of APP promoter regions to reduce expression
• Creation of induced pluripotent stem cell (iPSC) models for drug screening

Applications in Parkinson's Disease

GBA Gene Therapy

Heterozygous mutations in the [GBA](/genes/gba) gene are the most common genetic risk factor for PD. Prime editing can:

• Correct pathogenic GBA mutations
• Restore glucocerebrosidase enzymatic activity
• Reduce [alpha-synuclein](/proteins/alpha-synuclein) aggregation associated with GBA deficiency

LRRK2 Correction

[LRRK2](/genes/lrrk2) mutations are a major cause of familial PD. Prime editing offers:

• Correction of pathogenic LRRK2 variants (G2019S, R1441C/H/G)
• Modulation of LRRK2 kinase activity through precise amino acid changes
• Generation of isogenic cell models for studying LRRK2 pathology

SNCA Targeting

The [SNCA](/genes/snca) gene encodes alpha-synuclein, whose aggregation is central to PD pathogenesis. Prime editing approaches include:

• Correcting SNCA mutations (A53T, A30P, E46K)
• Reducing SNCA expression through promoter modifications
• Introducing protective variants

Applications in ALS

SOD1 Correction

Mutations in [SOD1](/genes/sod1) cause approximately 20% of familial ALS cases. Prime editing can:

• Correct over 190 known SOD1 pathogenic mutations
• Reduce mutant SOD1 protein aggregation
• Restore normal SOD1 enzymatic function

C9orf72 Targeting

Hexanucleotide repeat expansions in [C9orf72](/genes/c9orf72) are the most common cause of familial ALS and FTD. Prime editing offers:

• Reduction of repeat expansions
• Targeting of toxic dipeptide repeat proteins (DPRs)
• Modulation of [C9orf72](/entities/c9orf72) expression

FUS Gene Therapy

[FUS](/genes/fus) mutations cause a subset of aggressive ALS cases. Prime editing enables:

• Correction of pathogenic FUS mutations
• Restoration of proper RNA splicing
• Reduction of FUS protein mislocalization

Delivery Challenges

AAV Packaging Constraints

Adeno-associated virus (AAV) vectors are the leading delivery platform for CNS gene therapy, but face significant limitations:

• Size limit: AAV has a ~4.7 kb packaging capacity, insufficient for the nCas9-RT fusion (~5.2 kb)
• Solution: Split-intein systems, smaller Cas9 orthologs (SaCas9, Cas12f), or dual-AAV approaches

Viral vs. Non-Viral Delivery

| Method | Advantages | Disadvantages |
|--------|------------|---------------|
| AAV | Long-term expression, low immunogenicity | Size constraints, limited packaging |
| Lentivirus | Larger capacity, integration | Risk of insertional mutagenesis |
| Lipid nanoparticles (LNPs) | Safe, scalable | Transient expression |
| Virus-like particles (VLPs) | No genome, transient | Lower targeting efficiency |
| Electroporation | High efficiency (in vitro) | Tissue damage |

Brain Delivery Strategies

• Intrathecal delivery: Direct injection into cerebrospinal fluid
• Convection-enhanced delivery: Pressure-driven infusion into brain tissue
• Systemic delivery with [BBB](/entities/blood-brain-barrier)-crossing peptides: Peripheral administration with targeting ligands
• Focused ultrasound: Temporary BBB opening for enhanced CNS penetration

Current Preclinical Pipeline

Research Stage

Multiple research groups are advancing prime editing for neurodegenerative diseases:

Key Research Milestones

• 2019: Prime editing first described (Liu et al.)
• 2020-2022: Base editing and prime editing applied to neurodegenerative disease models
• 2023: Reviews highlight prime editing potential for hereditary neurological disorders[@bck2025]
• 2024-2025: Advanced delivery systems in preclinical development

Company Landscape

Several biotechnology companies are developing prime editing therapies:

• Prime Medicine — Lead program in liver diseases, expanding to CNS
• Beam Therapeutics — Base editing focus, developing dual base/prime editing
• Verve Therapeutics — Cardiovascular applications, technology applicable to CNS
• Excision BioTherapeutics — CRISPR-based approaches for CNS disorders

Key Researchers

Key academic researchers advancing prime editing for neurological diseases include:

• Keith J. Liu — Pioneer of prime editing technology (Harvard/MIT)
• David R. Liu — Developed prime editing and base editing (Broad Institute)
• Jean-Pierre Tremblay — Research on prime editing for neurodegenerative diseases[@bck2025]
• Katherine Godbout — Authored comprehensive review of prime editing for neurodegenerative diseases[@bck2025]

Therapeutic Outlook

Prime editing represents a promising approach for treating hereditary neurodegenerative diseases, with several advantages over existing gene therapy modalities:

Challenges Remaining

• Delivery: Efficient CNS delivery remains the primary obstacle
• Efficiency: Editing efficiency in post-mitotic neurons requires optimization
• Immune response: Pre-existing immunity to Cas9 proteins
• Clinical translation: Regulatory pathway for prime editing therapies

Future Directions

• Development of compact prime editing systems for AAV delivery
• Combination with gene delivery optimization for CNS targeting
• Clinical trials for hereditary neurological diseases with well-defined genetic targets

Recent Research (2024-2026)

Key Publications

See Also

• [Gene Therapy for Neurodegeneration](/therapeutics/gene-therapy-neurodegeneration)
• CRISPR Applications in Neurology
• APP Gene and Alzheimer's Disease
• LRRK2 and Parkinson's Disease
• SOD1 and ALS

External Links

• [PubMed - Prime Editing Research](https://pubmed.ncbi.nlm.nih.gov/?term=prime+editing+neurodegenerative)
• [ClinicalTrials.gov - Gene Editing Trials](https://clinicaltrials.gov/?term=prime+editing)
• [Nature - Prime Editing Collection](https://www.nature.com/collections/prime-editing)
• [Addgene - Prime Editing Resources](https://www.addgene.org/prime-editing/)

References